Skip to main content
Journal cover image

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

Publication ,  Journal Article
Wikstrand, CJ; Reist, CJ; Archer, GE; Zalutsky, MR; Bigner, DD
Published in: J Neurovirol
April 1998

Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important than within the central nervous system, due to the diffuse infiltrative nature of primary glial tumor cell growth. Whether ultimate effect moieties are immunoglobulins, fragments and/or their constructs with drugs, toxins, radionuclides, or immune cells, the specificity of effector: cell surface marker is crucial. This review describes the identification, immunologic characterization, and biologic behavior of a transmembrane tumor-specific altered growth factor receptor molecule which may well serve as a mediator of multiple immunotherapeutic approaches: the class III variant of the epidermal growth factor receptor, EGFRvIII.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Neurovirol

DOI

ISSN

1355-0284

Publication Date

April 1998

Volume

4

Issue

2

Start / End Page

148 / 158

Location

United States

Related Subject Headings

  • Virology
  • Molecular Sequence Data
  • Microscopy, Fluorescence
  • Mice, Nude
  • Mice
  • Immunotherapy
  • Immunohistochemistry
  • Humans
  • Glioma
  • ErbB Receptors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wikstrand, C. J., Reist, C. J., Archer, G. E., Zalutsky, M. R., & Bigner, D. D. (1998). The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol, 4(2), 148–158. https://doi.org/10.3109/13550289809114515
Wikstrand, C. J., C. J. Reist, G. E. Archer, M. R. Zalutsky, and D. D. Bigner. “The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.J Neurovirol 4, no. 2 (April 1998): 148–58. https://doi.org/10.3109/13550289809114515.
Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol. 1998 Apr;4(2):148–58.
Wikstrand, C. J., et al. “The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.J Neurovirol, vol. 4, no. 2, Apr. 1998, pp. 148–58. Pubmed, doi:10.3109/13550289809114515.
Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol. 1998 Apr;4(2):148–158.
Journal cover image

Published In

J Neurovirol

DOI

ISSN

1355-0284

Publication Date

April 1998

Volume

4

Issue

2

Start / End Page

148 / 158

Location

United States

Related Subject Headings

  • Virology
  • Molecular Sequence Data
  • Microscopy, Fluorescence
  • Mice, Nude
  • Mice
  • Immunotherapy
  • Immunohistochemistry
  • Humans
  • Glioma
  • ErbB Receptors